Human RCTPubMed ID: 36449413·2022

STEP 3: Semaglutide for Weight Management in Severe Obesity

Wadden TA, Hollander P, Klein S, et al.

New England Journal of Medicine, 2022 · n = 803

Key finding

Semaglutide 2.4mg achieved mean weight loss of 17.4% (≥21% in 38% of patients) versus 2.7% placebo; improved diabetes control (HbA1c -1.2%).

Summary

Phase 3b trial evaluating semaglutide in adults with severe obesity (BMI ≥35 kg/m²) with or without weight-related comorbidities.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

Semaglutide Effects on Heart Failure Symptoms in HFmrEF

JAMA Cardiology · 2022 · Human Pilot